DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

360 Delgado PL, Charney DS, Price LH, et al. Serotonin function
and the mechanism of antidepressant action. Reversal of antidepressant-induced
remission by rapid depletion of plasma
tryptophan. Arch Gen Psychiatry, 1990, 47:411–418.
Fox MA, Andrews AM, Wendland JR, et al. A pharmacological
analysis of mice with a targeted disruption of the serotonin
transporter. Psychopharmacology (Berl), 2007, 195:147–166.
Gaddum JH, Picarelli ZP. Two kinds of tryptamine receptors. Br
J Pharmacol, 1957, 12:323–328.
Gerdeman GL, Partridge JG, Lupica CR, Lovinger DM. It could
be habit forming: drugs of abuse and striatal synaptic plasticity.
Trends Neurosci, 2003, 26:184–192.
Gershon MD, Tack J. The serotonin signaling system: From
basic understanding to drug development for functional GI disorders.
Gastroenterology, 2007, 132:397–414.
Geyer MA, Vollenweider FX. Serotonin research: Contributions
to understanding psychoses. Trends Pharmacol Sci, 2008,
29:445–453.
Goto Y, Otani S, Grace AA. The Yin and Yang of dopamine
release: A new perspective, Neuropharmacology, 2007,
53:583–587.
Gonzalez-Maeso J, Weisstaub NV, Zhou M, et al. Hallucinogens
recruit specific cortical 5-HT 2A
receptor-mediated signaling
pathways to affect behavior. Neuron, 2007, 53:439–452.
Gray JA, Roth BL. Paradoxical trafficking and regulation of
5-HT 2A
receptors by agonists and antagonists. Brain Res Bull,
2001, 56:441–451.
Grailhe R, Waeber C, Dulawa SC, et al. Increased exploratory
activity and altered response to LSD in mice lacking the
5-HT(5A) receptor. Neuron, 1999, 22:581–591.
Hazelwood LA, Free RB, Sibley DR. Dopamine receptorinteracting
proteins. In The Dopamine Receptors (Neve KA,
ed.). Humana Press, Totowa, NJ, 2009.
Heidbreder C. Selective antagonism at dopamine D 3
receptors
as a target for drug addiction pharmacotherapy: a review of
preclinical evidence. CNS Neurol Disord Drug Targets, 2008,
7:410–421.
Hedlund PB, Danielson PE, Thomas EA. No hypothermic
response to serotonin in 5-HT7 receptor knockout mice. Proc
Natl Acad Sci USA, 2003, 100:1375–1380.
Holmes A, Lachowicz JE, Sibley DR. Phenotypic analysis of
dopamine receptor knockout mice; recent insights into the
functional specificity of dopamine receptor subtypes.
Neuropharmacology, 2004, 47:1117–1134.
Hornykiewicz O. Dopamine miracle: From brain homogenate to
dopamine replacement. Mov Disord, 2002, 17:501–508.
Hoyer D, Clarke DE, Fozard JR, et al. International Union of
Pharmacology classification of receptors for 5-hydroxytryptamine
(serotonin). Pharmacol Rev, 1994, 46:157–203.
Humphrey PP, Aperley E, Feniuk W, Perren MJ. A rational
approach to identifying a fundamentally new drug for the treatment
of migraine. In Cardiovascular Pharmacology of 5-
Hydroxytryptamine: Prospective Therapeutic Applications.
(Saxena PR, Wallis DI, Wouters W, Bevan P, eds.). Kluwer
Academic Publishers, Dordrecht, Netherlands, 1990, pp.
417–431.
Jensen AA, Davies PA, Bräuner-Osborne H, Krzywkowski K,
3B but which 3B? And that’s just one of the questions: the heterogeneity
of human 5-HT 3
receptors. Trends Pharmacol Sci,
2008, 29:437–444.
SECTION II
NEUROPHARMACOLOGY
Jose PA, Eisner GM, Felder RA. Renal dopamine receptors in
health and hypertension. Pharmacol Ther, 1998, 80:149–182.
Jouvet M. Sleep and serotonin: an unfinished story.
Neuropsychopharmacology, 1999, 21(suppl 2):24S–27S.
Joyce JN, Millan MJ. Dopamine D3 receptor agonists for protection
and repair in Parkinson’s disease. Curr Opin Pharmacol,
2007, 7:100–105.
Kaumann AJ, Levy FO. 5-hydroxytryptamine receptors in the
human cardiovascular system. Pharmacol Ther, 2006, 111:
674–706.
Kebabian JW, Calne DB. Multiple receptors for dopamine.
Nature, 1979, 277:93–96.
Kebabian JW, Greengard P. Dopamine-sensitive adenyl cyclase:
possible role in synaptic transmission. Science, 1971,
174:1346–1349.
King MV, Marsden CA, Fone KC. A role for the 5-HT 1A
, 5-HT 4
and 5-HT 6
receptors in learning and memory. Trends
Pharmacol Sci, 2008, 29:482–492.
Lee SP, So CH, Rashid AJ, et al. Dopamine D1 and D2 receptor
co-activation generates a novel phospholipase C-mediated calcium
signal. J Biol Chem, 2004, 279:35671–35678.
Lesch KP, Zeng Y, Reif A, Gutknecht L. Anxiety-related traits
in mice with modified genes of the serotonergic pathway. Eur
J Pharmacol, 2003, 480:185–204.
Liu IS, Seeman P, Sanyal S, et al. Dopamine D 4
receptor variant
in Africans, D4valine194glycine, is insensitive to dopamine
and clozapine: report of a homozygous individual. Am J Med
Genet, 1996, 61:277–282.
Lucki I. The spectrum of behaviors influenced by serotonin. Biol
Psychiatry, 1998, 44:151–162.
Maricq AV, Peterson AS, Brake AJ, et al. Primary structure and
functional expression of the 5HT3 receptor, a serotonin-gated
ion channel. Science, 1991, 254:432–437.
Mehrotra S, Gupta S, Chan KY, et al. Current and prospective
pharmacological targets in relation to antimigraine action.
Naunyn Schmiedebergs Arch Pharmacol, 2008, 378:371–394.
Meltzer HY, Huang M. In vivo actions of atypical antipsychotic
drug on serotonergic and dopaminergic systems. Prog Brain
Res, 2008, 172:177–197.
Mu Q, Johnson K, Morgan PS, et al. A single 20 mg dose of the
full D1 dopamine agonist dihydrexidine (DAR-0100)
increases prefrontal perfusion in schizophrenia. Schizophr Res,
2007, 94:332–341.
Nebigil CG, Choi DS, Dierich A. Serotonin 2B receptor is
required for heart development. Proc Natl Acad Sci USA,
2000, 97:9508–9513.
Neve KA, Seamans JK, Trantham-Davidson H. Dopamine receptor
signaling. J Recept Signal Transduct Res, 2004, 24:165–205.
Parks CL, Robinson PS, Sibille E, et al. Increased anxiety of
mice lacking the serotonin1A receptor. Proc Natl Acad Sci
USA, 1998, 95:10734–10739.
Peroutka SJ, Snyder SH. Multiple serotonin receptors: differential
binding of [ 3 H]5-hydroxytryptamine, [ 3 H]lysergic acid
diethylamide and [ 3 H]spiroperidol. Mol Pharmacol, 1979,
16:687–699.
Rankin ML, Hazelwood LA, Free RB, et al. Molecular pharmacology
of the dopamine receptors. In Dopamine Handbook
(al Ile, ed.). Oxford University Press, New York, 2009.
Roth BL. Drugs and valvular heart disease. N Engl J Med, 2007,
356:6–9.